Windlas BiotechNSE:WINDLAS +0.05%90 Days Payable is 147.99 as of Mar. 2026, which is 40% above its 10-year median of 105.59. GuruFocus rates NSE:WINDLAS with a GF Score™ of 90/100 and a GF Value™ of ₹936.98 (Fairly Valued). The stock has 1 warning sign investors should review. Among 920 Drug Manufacturers companies, Windlas Biotech ranks better than 69.24% on this metric.
The historical rank and industry rank for Windlas Biotech's Days Payable or its related term are showing as below:
NSE:WINDLAS'
s Days Payable Range Over the Past 10 Years
Min: 62.18 Med: 105.59 Max: 132.88
Current: 130.71
During the past 8 years, Windlas Biotech's highest Days Payable was 132.88. The lowest was 62.18. And the median was 105.59.
NSE:WINDLAS's Days Payable is ranked better than 69.24% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:WINDLAS: 130.71
Windlas Biotech's Days Payable
increased
from Mar. 2025 (121.90) to Mar. 2026 (147.99).
It may suggest that Windlas Biotechdelayed paying its suppliers.
Windlas Biotech Days Payable Related Terms
Windlas Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Windlas Biotech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Days Payable of 147.99 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Windlas Biotech and its competitors. This is 40% above median its historical median of 105.59. Over the past decade, Windlas Biotech's Days Payable has ranged from 62.18 to 132.88. According to the industry distribution chart, Windlas Biotech ranks #283 out of 920 companies in the Drug Manufacturers industry, placing it in the top 30.8%.
Is Windlas Biotech's Days Payable too high?
Windlas Biotech's current Days Payable of 147.99 is 40% above median its 10-year median of 105.59. Over the past 10 years, this metric has ranged from a low of 62.18 to a high of 132.88. The Drug Manufacturers industry median Days Payable is 90.84. Windlas Biotech's value of 147.99 is 62.9% above this industry median. Based on the distribution chart, Windlas Biotech ranks #283 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #283 out of 920 companies for Days Payable. This puts Windlas Biotech in the upper half of its industry. The industry median Days Payable is 90.84. Windlas Biotech's value of 147.99 is 62.9% above this benchmark. Historically, Windlas Biotech's own Days Payable has ranged from 62.18 to 132.88 over the past decade. While the company's 10-year median is 105.59 vs. the industry median of 90.84, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Days Payable of 147.99 is 62.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Days Payable is 147.99, which is 40% above median its own 10-year median of 105.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.30 — trading 8.3% below its estimated fair value. The current Days Payable is 147.99, which is 40% above median its 10-year median of 105.59 and 62.9% above the Drug Manufacturers industry median of 90.84. Windlas Biotech's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Days Payable is 147.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.30 is trading 8.3% below its estimated GF Value™ of ₹936.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Days Payable: 147.99 (40% above median its 10-year median of 105.59)
GF Value™: ₹936.98 vs. price of ₹859.30 (8.3% below fair value)
Industry Position: 62.9% above the Drug Manufacturers median (#283 of 920)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
90GF Score
Get the complete analysis for NSE:WINDLAS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
